<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Stone, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematologic neoplasms characterized by clonal hematopoiesis, cytopenias (ie, anemia, neutropenia, and/or thrombocytopenia), and dysplastic cellular morphology. Patients may experience symptoms related to anemia, infection, bleeding, and other complications of MDS, including variable rates of transformation to acute myeloid leukemia or bone marrow failure. The natural history, preferred treatments, and prognosis are associated with clinical and pathologic features that are used to diagnose and classify subtypes of MDS.</p><p>The epidemiology, clinical manifestations, pathologic features, diagnosis, and classification of MDS are reviewed in this topic.</p><p>Cytogenetic/genetic findings, pathophysiology, prognosis, and an overview of treatment of MDS are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4483.html" rel="external">"Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16122.html" rel="external">"Overview of the treatment of myelodysplastic syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>MDS are seen mostly in older adults. The precise incidence of MDS is not well-defined, in part, due to variable clinical presentations and evolving diagnostic criteria.</p><p>The annual incidence of MDS is approximately 4 per 100,000 people, according to the United States Surveillance, Epidemiology, and End Results database [<a href="#rid1">1</a>]. The median age at presentation is 70 years, and the risk of developing MDS increases with age. Disease onset before age 50 is unusual, and presentation in children is rare, except for therapy-related MDS and MDS arising in the context of a germline predisposition [<a href="#rid2">2</a>]. There is a male predominance in most categories of MDS, except for MDS with del(5q), which is more common in females.</p><p>MDS caused by germline predisposition is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Clinical manifestations of MDS are variable. Some patients present with fatigue, infections, bruising, or other manifestations of cytopenias, while others are asymptomatic and come to medical attention because of findings from routine blood counts.</p><p class="headingAnchor" id="H769050155"><span class="h2">Cytopenias</span><span class="headingEndMark"> — </span>Anemia is the most common cytopenia associated with MDS and may manifest as fatigue, weakness, exercise intolerance, loss of appetite, angina, dizziness, cognitive impairment, or an altered sense of well-being [<a href="#rid3">3-8</a>]. Fatigue is nearly ubiquitous and is often out of proportion to the degree of anemia. Less commonly, complications of leukopenia (eg, infections, gingivitis) or thrombocytopenia (eg, easy bruising, bleeding) are present. Physical findings are nonspecific, but may include pallor, petechiae, purpura, mucosal ulceration/gingivitis, or stigmata of infections.</p><p>Hepatomegaly, splenomegaly, and lymphadenopathy are uncommon and, if present, suggest an alternative diagnosis, such as a lymphoma. Systemic symptoms, such as fever, sweats, or weight loss are uncommon and generally represent late manifestations of MDS or transformation to acute leukemia.</p><p class="headingAnchor" id="H2301298"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Patients with MDS may develop infections related to neutropenia and granulocyte dysfunction [<a href="#rid9">9</a>].</p><p>The incidence of infections is not well documented, but in a retrospective study of 273 patients with lower-risk MDS, infections accounted for more than one-third of deaths; pneumonia accounted for 40 percent of the infectious deaths [<a href="#rid10">10</a>]. Bacterial infections predominate, with the skin being the most common site [<a href="#rid9">9</a>]. Although fungal, viral, and mycobacterial infections can occur, they are rare in the absence of treatment with immunosuppressive agents.</p><p>Abnormalities of adaptive immunity may also occur, even though lymphocytes are not generally derived from the malignant clone. Immunoglobulin production is variably affected, with hypogammaglobulinemia, polyclonal hypergammaglobulinemia, and monoclonal gammopathy reported in 13, 30, and 12 percent of patients, respectively [<a href="#rid11">11</a>].</p><p>Evaluation and treatment of infections in patients with MDS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Neutropenia'</a>.)</p><p class="headingAnchor" id="H2301305"><span class="h2">Autoimmune/inflammatory conditions</span><span class="headingEndMark"> — </span>Autoimmune and inflammatory conditions are more prevalent in patients with MDS than in the general population. </p><p>Autoimmune abnormalities have been reported in 10 to 20 percent of patients of MDS and are more common in patients with higher-risk disease [<a href="#rid12">12</a>]. Analysis of US Surveillance, Epidemiology, and End Results (SEER) cancer registry data reported that autoimmune phenomena were more common among 2471 patients with MDS compared with 42,886 controls (23 percent versus 14 percent, respectively) [<a href="#rid13">13</a>]. The most common autoimmune conditions in patients with MDS were chronic rheumatic heart disease (7 percent), rheumatoid arthritis (6 percent), pernicious anemia (6 percent), psoriasis (2 percent), and polymyalgia rheumatica (2 percent). Other autoimmune abnormalities include Sweet syndrome, pericarditis, pleural effusions, skin ulcerations, iritis, myositis, peripheral neuropathy, and pure red cell aplasia.</p><p>Inflammaging refers to chronic, low-grade, systemic inflammation associated with physiologic aging [<a href="#rid14">14</a>]. Compared with representative Medicare controls, the prevalence of inflammaging disorders was increased in patients with MDS [<a href="#rid15">15</a>]. Examples include antecedent cardiovascular diseases (52 versus 36 percent; odds ratio [OR] 1.42 [95% CI 1.37-1.48]), pulmonary conditions (28 versus 19 percent; OR 1.27 [95% CI 1.22-1.33]), metabolic disorders (48 versus 33 percent; OR 1.28 [95% CI 1.23-1.34]), bone and joint diseases (50 versus 38 percent; OR 1.45 [95% CI 1.41-1.51]), and others (eg, fatty liver disease, chronic renal disease).</p><p class="headingAnchor" id="H4008672"><span class="h2">Acquired hemoglobin H disease</span><span class="headingEndMark"> — </span>Acquired hemoglobin H disease (also called acquired alpha thalassemia) has been reported in &lt;10 percent of cases of MDS [<a href="#rid16">16-20</a>]. Acquired hemoglobin H disease is associated with microcytosis, poikilocytosis, hypochromia, and hemoglobin H-containing red cells  (<a class="graphic graphic_picture graphicRef77536" href="/z/d/graphic/77536.html" rel="external">picture 1</a>). Acquired mutation of <em>ATRX</em> (an X-linked gene encoding a DNA helicase) and acquired deletions of alpha globin genes have been linked to the presence of hemoglobin H [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes", section on 'ATRX variants and alpha thalassemia'</a>.)</p><p class="headingAnchor" id="H2301312"><span class="h2">Cutaneous manifestations</span><span class="headingEndMark"> — </span>Skin lesions are uncommon in patients with MDS, but Sweet syndrome (acute febrile neutrophilic dermatosis) may herald transformation to acute leukemia [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>Development of myeloid sarcoma is considered diagnostic of transformation to acute myeloid leukemia. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Myeloid sarcoma'</a>.)</p><p class="headingAnchor" id="H4292912352"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Evaluation of a patient suspected to have MDS involves clinical assessment, laboratory studies, and bone marrow examination.</p><p class="headingAnchor" id="H3217456030"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The history should elicit details regarding consequences or complications of cytopenias (eg, fatigue, infections, bruising). It should also evaluate other potential causes for cytopenias and/or dysplasia, including nutritional status, alcohol and drug use, medications, exposure to toxic chemicals, prior treatment with antineoplastic agents or radiotherapy, and risk factors for HIV infection. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Physical examination may reveal pallor, dyspnea, tachycardia, mucosal ulceration, manifestations of infections, and/or bleeding or bruising. Some patients may have splenomegaly, but adenopathy is uncommon.</p><p class="headingAnchor" id="H4008100"><span class="h2">Complete blood count</span><span class="headingEndMark"> — </span>Complete blood count (CBC) with leukocyte differential usually demonstrates anemia, while neutropenia and thrombocytopenia are more variable [<a href="#rid8">8</a>]. Isolated anemia is common, whereas isolated neutropenia, thrombocytopenia, or monocytosis without anemia is infrequent. Pancytopenia (ie, anemia, leukopenia, and thrombocytopenia) is present in up to half of patients at the time of diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Red blood cells</strong> – Anemia is generally associated with an inappropriately low reticulocyte response [<a href="#rid21">21</a>]. The mean corpuscular volume (MCV) is usually normal or macrocytic (&gt;100 femtoL), except for cases associated with acquired hemoglobin H disease, in which microcytosis is often seen. The red cell distribution width (RDW) is often increased, reflecting the variability in red blood cell size (anisocytosis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukocytes</strong> – Approximately one-half of patients with MDS have a reduced total white blood cell (WBC) count, usually resulting from absolute neutropenia [<a href="#rid21">21</a>]. Circulating immature neutrophils (myelocytes, promyelocytes, and myeloblasts) may be identified but, by definition, blasts constitute &lt;20 percent of the leukocyte differential count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelets </strong>– Variable levels of thrombocytopenia are present, but isolated thrombocytopenia is an uncommon manifestation of early MDS [<a href="#rid22">22</a>]. An exception is MDS with del(20q), which is more likely to manifest as isolated thrombocytopenia with minimal morphologic dysplasia [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">Thrombocytosis is less common in patients suspected of having MDS. In a single institution study, 8 percent of 388 patients presented with a high platelet count; there was a low incidence of spontaneous bleeding or thromboembolic events [<a href="#rid24">24</a>]. Thrombocytosis is most often associated with abnormalities of chromosome 5q and MDS with ring sideroblasts and mutated <em>SF3B1</em>. </p><p></p><p class="headingAnchor" id="H33613152"><span class="h2">Blood smear</span><span class="headingEndMark"> — </span>The peripheral blood smear usually demonstrates dysplasia in red cells and the white cells and may reveal platelet abnormalities  (<a class="graphic graphic_table graphicRef82345" href="/z/d/graphic/82345.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Red blood cells</strong> – Red blood cells (RBC) are usually normocytic or macrocytic, but some patients may have a population of hypochromic, microcytic red cells [<a href="#rid21">21</a>]. Macroovalocytosis is the most common morphologic abnormality, but elliptocytes, teardrop cells, stomatocytes, or acanthocytes (spur cells) may be seen. Basophilic stippling, Howell-Jolly bodies, and megaloblastoid nucleated RBCs may be seen on the blood smear  (<a class="graphic graphic_picture graphicRef85882" href="/z/d/graphic/85882.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef85883" href="/z/d/graphic/85883.html" rel="external">picture 3</a>). Reticulocytosis may reflect delayed reticulocyte maturation (so-called pseudo-reticulocytosis) or may indicate a superimposed autoimmune hemolytic anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>White blood cells</strong> – Dysplastic neutrophils are commonly found on the blood smear. Neutrophils may demonstrate increased size, abnormal nuclear lobation, and abnormal granularity. Granulocytes commonly display reduced segmentation (pseudo-Pelger-Huet abnormality), often accompanied by reduced or absent granulation  (<a class="graphic graphic_picture graphicRef71990" href="/z/d/graphic/71990.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef85881" href="/z/d/graphic/85881.html" rel="external">picture 5</a>) and/or ring-shaped nuclei or nuclear sticks [<a href="#rid25">25-28</a>]. Rarely, a pseudo-Chediak-Higashi anomaly  (<a class="graphic graphic_picture graphicRef71313" href="/z/d/graphic/71313.html" rel="external">picture 6</a>) or myelokathexis-like features (ie, lengthening and thinning of nuclear segments)  (<a class="graphic graphic_picture graphicRef78993" href="/z/d/graphic/78993.html" rel="external">picture 7</a>) may be evident [<a href="#rid29">29,30</a>]. Monocytes may appear immature or exhibit abnormalities of nuclear lobation. (See  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia", section on 'Severe congenital neutropenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelets</strong> – Platelets are usually morphologically normal. Less commonly, platelets may be smaller or larger than normal or hypergranular or hypogranular. Megakaryocytic fragments are not seen.</p><p></p><p class="headingAnchor" id="H47639590"><span class="h2">Bone marrow examination</span><span class="headingEndMark"> — </span>Bone marrow examination is an essential aspect of evaluation, diagnosis, and classification of MDS.</p><p class="headingAnchor" id="H3720304768"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>The bone marrow features single- or multi-lineage dysplasia  (<a class="graphic graphic_table graphicRef82345" href="/z/d/graphic/82345.html" rel="external">table 1</a>) and is usually hypercellular [<a href="#rid21">21,31</a>]. An adequate bone marrow aspirate should provide material for a 500-cell differential count and a cytologic evaluation of blasts and other cells. Morphologic evidence of dysplasia has limited reproducibility when dysplastic changes are not overt and may be complemented by immunophenotypic methods [<a href="#rid32">32,33</a>]. (See <a class="local">'Other analyses'</a> below.)</p><p>Characteristic morphologic features of MDS in bone marrow include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blasts</strong> – Myeloblasts are increased but, by definition, the blast percentage is &lt;20 percent [<a href="#rid21">21</a>]. Myeloblasts can be identified by their high nuclear:cytoplasmic ratio, easily visible nucleoli, fine nuclear chromatin, variable cytoplasmic basophilia, few or no cytoplasmic granules, and absent Golgi zone [<a href="#rid34">34,35</a>]. Auer rods within blasts  (<a class="graphic graphic_picture graphicRef78291" href="/z/d/graphic/78291.html" rel="external">picture 8</a>) are uncommon, but when present they are diagnostic for MDS with excess blasts, regardless of the percentage of blasts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloid cells</strong> – Impaired myeloid maturation is often readily apparent. There are variable percentages of granulocytic precursors and, not infrequently, a relative maturation arrest at the myelocyte stage [<a href="#rid36">36</a>]. In granulocytic precursors, the cytoplasm may mature more rapidly than the nucleus and cells may have large size, abnormal nuclear shape, and variable levels of cytoplasmic granularity [<a href="#rid37">37</a>]. Granulopoiesis may be displaced from its normal paratrabecular location to more central marrow spaces; clusters of immature cells may be located centrally in the marrow space rather than along the endosteal surface, a phenomenon known as abnormal localization of immature precursors (ALIP) [<a href="#rid38">38-41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythroid cells</strong> – Although erythroid hyperplasia (associated with ineffective erythropoiesis) is usually seen, red cell aplasia and/or hypoplasia also rarely occur [<a href="#rid42">42</a>]. Morphologic abnormalities in erythroid precursors include large size, nuclear multi-lobation, nuclear budding, and other abnormal forms. The cytoplasm of erythroid progenitors may show vacuolization, coarse or fine periodic acid-Schiff-positive granules, or ring sideroblasts [<a href="#rid38">38,43</a>]. Internuclear bridging characterized by chromatin threads that tether dissociated nuclei reflects impaired mitosis and may contribute to the addition and deletion of genetic material characteristic of MDS [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Megakaryocytes</strong> – Megakaryocytes are usually normal or increased in number and sometimes occur in clusters. Abnormal megakaryocytes, including large or very small mononuclear forms (micromegakaryocytes or "dwarf megakaryocytes"), megakaryocytes with multiple dispersed nuclei ("pawn ball megakaryocytes"), and hypogranular megakaryocytes, are common findings  (<a class="graphic graphic_picture graphicRef59897" href="/z/d/graphic/59897.html" rel="external">picture 9</a>) [<a href="#rid25">25,45,46</a>]. Non-lobulated or mononuclear megakaryocytes may also be identified, particularly in association with abnormalities of chromosome 5q.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other lineages </strong>– Reactive lymphocytosis, lymphoid aggregates, increased histiocytes/macrophages, and/or pseudo-Gaucher histiocytes may be seen. Increased numbers of mast cells, particularly when demonstrating spindled morphology or occurring in clusters of ≥15 cells, may be a manifestation of systemic mastocytosis, which sometimes accompanies MDS and other myeloid neoplasms (ie, systemic mastocytosis with associated myeloid neoplasm), particularly in cases that are associated with activating mutations in the <em>KIT</em> tyrosine kinase gene [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/103174.html" rel="external">"Systemic mastocytosis: Determining the subtype of disease", section on 'Systemic mastocytosis with an associated hematologic neoplasm'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrosis</strong> – Mild to moderate degrees of myelofibrosis are reported in up to one-half of patients with MDS, and marked fibrosis is found in 10 to 15 percent [<a href="#rid48">48-51</a>]. While myelofibrosis occurs in all subtypes of MDS, it is most common in therapy-related MDS [<a href="#rid52">52</a>]. Fibrosis generally takes the form of increased numbers and/or thickness of reticulin fibers (best detected with a silver impregnation stain); importantly, deposition of mature collagen (detected with a trichrome stain) is uncommon in MDS [<a href="#rid53">53</a>]. The degree of fibrosis should be graded using European consensus criteria  (<a class="graphic graphic_table graphicRef110228" href="/z/d/graphic/110228.html" rel="external">table 2</a>). (See <a class="local">'MDS/MPN syndromes'</a> below.)</p><p></p><p class="headingAnchor" id="H5152246"><span class="h3">Cytogenetic and molecular features</span><span class="headingEndMark"> — </span>Characterization of cytogenetic and molecular abnormalities is required for the diagnosis and classification of MDS, determining prognostic risk group, and selecting therapy. Importantly, certain cytogenetic/molecular features exclude the diagnosis of MDS. (See <a class="local">'Diagnosis'</a> below and <a class="local">'Classification'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chromosomal abnormalities</strong> – Chromosomal abnormalities are detected by chromosome banding techniques and fluorescence in situ hybridization (FISH). (See  <a class="medical medical_review" href="/z/d/html/4482.html" rel="external">"General aspects of cytogenetic analysis in hematologic malignancies"</a>.)</p><p></p><p class="bulletIndent1">Chromosomal abnormalities are seen in approximately one-half of cases of de novo (primary) MDS; the likelihood of karyotypic abnormalities is increased in patients with advanced MDS. Numerical abnormalities (ie, monosomy [loss of a chromosome] or trisomy) are more common than balanced translocations. Complex karyotypes (ie, multiple abnormalities) are found in 10 to 15 percent of patients.</p><p></p><p class="bulletIndent1">The most common numerical karyotypic abnormalities (eg, deletions of chromosome 5q, chromosome 7, others) and balanced translocations (eg, t(3;21), inv(3)/t(3;3), and t(11;16)) associated with MDS are described separately. (See  <a class="medical medical_review" href="/z/d/html/4483.html" rel="external">"Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations</strong> – Gene mutations can be detected by targeted gene panels. (See  <a class="medical medical_review" href="/z/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Detecting known mutations'</a>.)</p><p></p><p class="bulletIndent1">At least one oncogenic mutation is detected in nearly all cases of MDS. Mutations affect a broad range of cellular processes, including RNA splicing (eg, <em>SRSF2</em>, <em>U2AF1</em>, <em>SF3B1</em>), chromatin regulation (<em>EZH2</em>, <em>BCOR</em>, <em>ASXL1</em>), DNA damage response (<em>TP53</em>), lineage-specific transcription (eg, <em>RUNX1, GATA2</em>), DNA methylation (eg, <em>DNMT3A</em>, <em>TET2</em>, <em>IDH1</em>/<em>2</em>), and the cohesin complex (eg, <em>STAG2</em>) and RAS/MAPK signaling (<em>NRAS</em>, <em>KRAS</em>, <em>PTPN11</em>). Some mutations have independent prognostic significance in MDS.</p><p></p><p class="bulletIndent1">MDS-associated mutations and their contributions to disease pathophysiology are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4483.html" rel="external">"Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)"</a>.)</p><p></p><p class="headingAnchor" id="H2570921697"><span class="h3">Other analyses</span><span class="headingEndMark"> — </span>Other studies that may be useful include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytochemistry</strong> – Iron staining with Prussian blue is used to detect ring sideroblasts. Periodic acid-Schiff (PAS) staining can aid in detecting dyserythropoiesis; peroxidase, Sudan Black B, and alkaline phosphatase can highlight aberrant or incomplete myeloid differentiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunohistochemistry</strong> – Immunohistochemical stains can be useful adjuncts for identifying cellular lineage and/or the extent and aberrancy of cellular maturation. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythroid precursor cells</strong> – Staining for glycophorin (CD235a), transferrin receptor (CD71), and/or GATA1 can aid in detecting erythroid precursor cells.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blasts</strong> – Staining for CD34, CD117, CD33, myeloperoxidase, and lysozyme can assist in quantifying blasts and myeloid progenitors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Megakaryocyte dysplasia</strong> – Staining for CD41 and/or CD61 can aid in detection of dysplastic or immature megakaryocytes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lineage infidelity</strong> – Staining for myeloid and lymphoid markers can help to detect lineage infidelity, confirm the presence of bi- or tri-lineage dysplasia, and exclude a lymphoid origin of primitive blasts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flow cytometry</strong> – Multiparameter flow cytometry is not required for the diagnosis of MDS, but can be useful for assessing diagnostic and prognostic features of MDS [<a href="#rid54">54-60</a>]. Flow cytometry should be performed according to standardized methods proposed by the International Flow Cytometry Working Group of the European LeukemiaNet [<a href="#rid59">59,61</a>].</p><p></p><p class="headingAnchor" id="H37"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>MDS should be considered in any patient with unexplained cytopenia(s) or clinical findings associated with anemia, infections, or bleeding/bruising; morphologic dysplasia of blood or marrow; or unexplained bone marrow failure.</p><p>Diagnosis of MDS requires persistent cytopenias <strong>and</strong> &lt;20 percent blasts in peripheral blood (PB)/bone marrow (BM) <strong>plus either</strong> characteristic cytogenetic/molecular features <strong>or</strong> dysplastic morphology.</p><p>Diagnostic criteria for MDS are [<a href="#rid62">62,63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytopenia(s)</strong> – One or more cytopenias that cannot be explained by a drug, toxin, vitamin deficiency, infection, or other condition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemoglobin</strong> – &lt;10 g/dL (100 g/L)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Absolute neutrophil count (ANC)</strong> – &lt;1.8 x 10<sup>9</sup>/L (&lt;1800/microL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Platelets</strong> – &lt;100 x 10<sup>9</sup>/L (&lt;100,000/microL)</p><p></p><p class="bulletIndent1">While cytopenias associated with MDS are typically chronic (eg, ≥4 months), there is no required minimal duration.</p><p></p><p class="bulletIndent1">Note that some individuals have ANC &lt;1.5 x<sup> </sup>10<sup>9</sup>/L with no associated infections or other cytopenias; such variants are most often encountered in individuals of African descent, Sephardic Jews, West Indians, Yemenites, Greeks, and Arabs. This condition was formerly called benign ethnic neutropenia and most often associated with the Duffy null [Fy(a-b-)] red blood cell phenotype. (See  <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Normal variants &lt;1500/microL'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blasts</strong> – &lt;20 percent blasts in bone marrow or peripheral blood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysplasia</strong> – Significant dysplasia in ≥10 percent of cells in a given hematopoietic lineage (ie, erythroid precursors, granulocytes, megakaryocytes) in bone marrow or peripheral blood, without another cause for dysplasia  (<a class="graphic graphic_table graphicRef82345" href="/z/d/graphic/82345.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">For the megakaryocytic lineage, micromegakaryocytes are the most specific indicator of MDS; a higher threshold of dysplasia may be warranted when other types of dysmegakaryopoiesis are included [<a href="#rid31">31,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytogenetic/molecular abnormalities</strong> – Certain cytogenetic and/or molecular abnormalities in patients with persistent cytopenia(s) are MDS-defining, irrespective of dysplasia. Conversely, some cytogenetic/molecular abnormalities exclude the diagnosis of MDS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS-defining</strong> – The following findings in association with cytopenia(s) are sufficient to diagnose MDS:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mutated <em>SF3B1</em> (≥10 percent variant allele frequency [VAF])</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>del(5q) with up to 1 additional cytogenetic abnormality, except -7/del(7q)</p><p></p><p class="bulletIndent2">In the absence of dysplasia or abnormal blood counts, other clonal karyotypic changes lack diagnostic specificity and are not sufficient criteria by themselves for a diagnosis of MDS; examples include del(Y), trisomy 8, and del(20q).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS-excluding</strong> – The following abnormalities are associated with AML and exclude the diagnosis of MDS:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>t(8;21)(q22;q22); <em>RUNX1::RUNX1T1</em> (previously <em>AML1::ETO</em>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB::MYH11</em></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>t(15;17)(q22;q21.1); <em>PML::RARA</em></p><p></p><p>The role of cytogenetic and molecular findings in classification of MDS is discussed below. (See <a class="local">'Classification'</a> below.)</p><p class="headingAnchor" id="H1358690583"><span class="h1">CLASSIFICATION</span></p><p class="headingAnchor" id="H1607923117"><span class="h2">Preferred classification systems</span><span class="headingEndMark"> — </span>There are two contemporary classification systems for MDS that share many features, but they differ in significant ways, as described below. The two systems are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Consensus Classification (ICC)</strong> [<a href="#rid62">62</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>World Health Organization 5</strong><strong><sup>th</sup></strong><strong> edition (WHO5) </strong>[<a href="#rid63">63</a>]</p><p></p><p>We consider use of either ICC or WHO5 acceptable, and we prefer them over earlier classification systems because they better integrate cytogenetic and molecular features of MDS that are associated with prognosis and treatment. While both schemes use the abbreviation "MDS", ICC retained the name "Myelodysplastic syndromes," whereas WHO5 renamed these entities "Myelodysplastic neoplasms".</p><p>Both ICC and WHO5 recognize the significance of bone marrow blast count, extent of dysplasia, and cytogenetic and molecular abnormalities for categorizing MDS. However, they differ regarding their overall organization, category labels, diagnostic criteria, distinctions between MDS with excess blasts and acute myeloid leukemia (AML), and classification of treatment related MDS and MDS associated with germline genetic abnormalities. Broader discussion of ICC, WHO5, and other schemes for classification of hematologic malignancies is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myelodysplastic neoplasms/syndromes (MDS)'</a>.)</p><p class="headingAnchor" id="H168147456"><span class="h2">International Consensus Classification (ICC)</span><span class="headingEndMark"> — </span>The International Consensus Classification (ICC) categorizes MDS according to specific cytogenetic or karyotypic abnormalities, the degree of dysplasia, or presence of excess blasts [<a href="#rid62">62</a>].</p><p>Compared with the revised World Health Organization 4<sup>th</sup> edition (WHO4R), significant changes in ICC include the designation "MDS/AML" for cases of MDS with 10 to 19 percent blasts; MDS with multi-hit <em>TP53</em> mutations is grouped with "Myeloid neoplasms with mutated <em>TP53</em>" (rather than with other MDS subtypes); MDS that arises after cytotoxic treatment is indicated with the qualifier, "therapy-related"; MDS in children is considered a distinct entity; and cases of MDS associated with a pathogenic germline gene variant are grouped in "Pediatric and/or germline mutation-associated disorders". </p><p>MDS is classified using the following criteria, according to ICC:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific genetic or karyotypic abnormalities</strong> – Two subtypes are defined according to specific molecular or cytogenetic features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with mutated </strong><strong><em>SF3B1</em></strong> – This category was previously called MDS with ring sideroblasts, but ICC criteria do not require either dysplasia or ring sideroblasts. Diagnostic criteria are: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Mutant<em> SF3B1</em> (≥10 percent variant allele frequency [VAF]) without multi-hit<em> TP53</em> <em>or RUNX1</em> mutations</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – Bone marrow (BM) blasts &lt;5 percent and peripheral blood (PB) blasts &lt;2 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – Any cytogenetic abnormality, except isolated del(5q), - 7/del(7q), abn3q26.2, or complex karyotype</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytopenias/cytoses</strong> – ≥1 cytopenia </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – ≥1 dysplastic lineage (not required) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with deletion of chromosome 5q</strong> – This category is defined by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – del(5q) or monosomy 5, with up to one additional cytogenetic abnormality, except -7/del(7q)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Any mutations, except multi-hit<em> TP53</em> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM blasts &lt;5 percent and PB blasts &lt;2 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytopenias/cytoses</strong> – ≥1 cytopenia; thrombocytosis is allowed </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – ≥1 dysplastic lineage</p><p></p><p class="bulletIndent1">MDS with multi-hit <em>TP53</em> mutations is grouped with other <em>TP53</em>-mutated myeloid neoplasms, rather than MDS, per se. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myeloid neoplasms with mutated TP53'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysplasia</strong> – There are several categories of MDS, not otherwise specified (NOS), with varying degrees of dysplasia, defined as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS, NOS without dysplasia</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – No dysplastic lineages</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytopenias/cytoses</strong> – ≥1 cytopenia, but no cytoses</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM blasts &lt;5 percent and PB blasts &lt;2 percent </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – 7/del(7q) or complex cytogenetics</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Any mutations, except multi-hit <em>TP53</em> or <em>SF3B1</em> (≥10 percent VAF)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with single lineage dysplasia</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – 1 dysplastic lineage</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytopenias/cytoses</strong> – ≥1 cytopenia; no cytoses</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM blasts &lt;5 percent and PB blasts &lt;2 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – Any cytogenetics abnormalities, except del(5q) with other associated findings</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Any mutations, except multi-hit <em>TP53</em> and mutated <em>SF3B1</em> with other associated findings</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with multilineage dysplasia</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – ≥2 dysplastic lineages</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytopenias/cytoses</strong> – ≥1 cytopenia; no cytoses</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM blasts &lt;5 percent and PB blasts &lt;2 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – Any cytogenetic abnormalities, except del(5q) with other associated findings </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Any mutations, except multi-hit <em>TP53</em> and not meeting criteria for MDS with mutated <em>SF3B1 </em>with other associated findings</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excess blasts</strong> – The presence of excess blasts supersedes any of the above MDS subtypes, except for MDS with mutated <em>TP53</em>. ICC has a single category of MDS with excessive blasts and describes cases with 10 to 19 percent blasts in a new category, "MDS/AML".</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with excess blasts</strong> – This category is defined by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM blasts 5 to 9 percent and/or PB blasts 2 to 9 percent (or 1 percent on two occasions)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – Any cytogenetic abnormalities</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Any mutations, except multi-hit <em>TP53</em> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytopenias/cytoses</strong> – ≥1 cytopenia; no cytoses</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – Typically ≥1 dysplastic lineage</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS/AML</strong> – This category is defined by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – MDS with 10 to 19 percent BM or PB blasts</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – Any cytogenetics abnormalities except AML-defining abnormalities</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Any mutations, except <em>NPM1, bZIP, CEBPA, </em>or<em> TP53</em></p><p></p><p class="headingAnchor" id="H2473161434"><span class="h2">World Health Organization 5th edition (WHO5)</span><span class="headingEndMark"> — </span>The World Health Organization 5<sup>th</sup> edition (WHO5)<strong> </strong>categorizes MDS according to either defining genetic abnormalities or morphology [<a href="#rid63">63</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Key features</strong> – Important features of WHO5, compared with WHO4R and earlier classification schemes, include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New labels and diagnostic criteria for certain MDS subtypes, including distinct subtypes for MDS with bone marrow hypoplasia or fibrosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike the ICC, WHO5 continues to distinguish MDS from most forms of AML using a 20 percent blast threshold</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eliminated "MDS, unclassifiable"</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assigns treatment-related myeloid neoplasms to a new category, "Myeloid neoplasms post-cytotoxic therapy"</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Retains MDS with germline pathogenic variants in the MDS category</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Describes childhood MDS as a distinct category</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>WHO5 classification of MDS</strong> – Categories are:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defining genetic abnormalities</strong> – There are three subtypes defined according to genetic features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with low blasts and isolated del(5q)</strong><em> </em>– Defined by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – 5q deletion or monosomy 5, alone or with one other abnormality other than monosomy 7 or 7q deletion</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM blasts &lt;5 percent in BM and PB blasts &lt;2 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – Mutated <em>SF3B1</em> or <em>TP53</em> mutation (not multi-hit) permitted, if other criteria are met</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with low blasts and </strong><strong><em>SF3B1</em></strong><strong> mutation</strong> – Defined by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – <em>SF3B1</em> mutation</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – Absence of 5q deletion, monosomy 7, or complex karyotype</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM blasts &lt;5 percent and PB blasts &lt;2 percent </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Morphology </strong>– ≥15 percent ring sideroblasts can substitute for <em>SF3B1</em> mutation in making this diagnosis </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with biallelic </strong><strong><em>TP53</em></strong><strong> inactivation</strong> – Defined by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutations</strong> – ≥2 <em>TP53</em> mutations or one mutation with evidence of <em>TP53</em> copy number loss or copy neutral loss of heterozygosity. </p><p></p><p class="bulletIndent3">Biallelic<em> TP53</em> abnormalities may be due to multiple mutations or a single mutation with either concurrent deletion of the other allele or copy-neutral loss of heterozygosity (CN-LOH); such "multi-hit"<em> TP53</em> mutations lack residual p53 activity. <em>TP53</em> VAF ≥50 percent is considered presumptive, but not definitive, evidence of loss on the other normal allele or copy neutral loss of heterozygosity. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics</strong> – Typically complex cytogenetics.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blasts</strong> – BM and PB blasts &lt;20 percent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphologically defined</strong> – Cases of MDS without a defining genetic abnormality are classified as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with low blasts</strong> – BM blasts &lt;5 percent and PB blasts &lt;2 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS, hypoplastic</strong> – Bone marrow cellularity ≤25 percent (adjusted for age) </p><p></p><p class="bulletIndent2">This subtype is associated with T cell-mediated immune attack on hematopoietic stem and progenitor cells, oligoclonal expansion of CD8 cytotoxic T-cells (which overproduce interferon gamma and/or tumor necrosis factor alpha), and response to treatments used for aplastic anemia (eg, anti-thymocyte globulin). (See  <a class="medical medical_review" href="/z/d/html/7158.html" rel="external">"Treatment of aplastic anemia in adults", section on 'Treatments'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS with increased blasts</strong> <strong>(MDS-IB)</strong> – There are three categories:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>MDS-IB1</strong> – BM blasts 5 to 9 percent or PB blasts 2 to 4 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>MDS-IB2</strong> – BM blasts 10 to 19 percent, PB blasts 5 to 19 percent; or Auer rods with any number of blasts up to 19 percent</p><p></p><p class="bulletIndent3">This category corresponds to MDS/AML by the ICC [<a href="#rid62">62</a>]. (See <a class="local">'International Consensus Classification (ICC)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>MDS with increased blasts and fibrosis</strong> – BM fibrosis (WHO grade 2-3 of 3) with BM blasts 5 to 19 percent and PB blasts 2 to 19 percent </p><p></p><p class="headingAnchor" id="H39"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>MDS must be distinguished from other conditions that are associated with dysplasia, cytopenias, and/or clonality; some conditions in the differential diagnosis exhibit more than one of these features.</p><p class="headingAnchor" id="H1389309831"><span class="h2">Causes of dysplasia</span><span class="headingEndMark"> — </span>Morphologic dysplasia, even when prominent, is not definitive evidence of a malignant or clonal disorder. The differential diagnosis also includes nonmalignant causes. Distinguishing MDS from other causes requires correlating morphologic findings with clinical presentation, exposures, and family history and confirming the diagnosis by laboratory testing (eg, assays for vitamin and mineral levels, toxins, and serology), cytogenetics, and molecular testing.</p><p>Clonal disorders associated with dysplasia that must be distinguished from MDS are discussed below. (See <a class="local">'Clonal disorders'</a> below.)</p><p>The differential diagnosis of hematologic dysplasia is broad and includes [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutritional deficiencies</strong> – Deficiency of vitamin B12, folate, or copper, or zinc excess (likely due to impaired copper absorption) should be excluded by clinical evaluation and laboratory testing. (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'Copper deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults", section on 'Older adults'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic exposures</strong> – Excess alcohol and heavy metal exposure (eg, arsenic, lead, zinc) should be excluded by clinical history and laboratory testing. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs and biologic agents</strong> – Numerous drugs and biologic agents can be associated with dysplasia, including chemotherapy, cotrimoxazole, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a>, <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, and granulocyte colony-stimulating factor [<a href="#rid65">65-70</a>]. Dysplastic changes associated with medications may be seen in all bone marrow lineages and may be accompanied by macrocytosis, reduced neutrophil lobulation, and cytopenias. In most cases, dysplastic changes are reversible over a period of weeks after reduction or discontinuation of the offending medication. Repeat bone marrow examination may be necessary to confirm the improvement in some cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – HIV infection is associated with dysplastic hematopoiesis and variable degrees of cytopenias. HIV infection should be excluded by screening serology. Dysplasia in people living with HIV infection may result from medications, opportunistic infection, and/or a direct effect of HIV on hematopoietic progenitors. MDS in people living with HIV infection is more likely to have complex cytogenetics (including monosomy 7 and del(7q)) and is associated with shorter survival compared with non-HIV-infected patients [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/6679.html" rel="external">"HIV-associated cytopenias"</a>.)</p><p></p><p class="bulletIndent1">Parvovirus B19 can cause reticulocytopenia, erythroblastopenia, and giant pronormoblasts. (See  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Transient aplastic crisis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital disorders</strong> – Congenital dyserythropoietic anemia and Pelger-Huët anomaly can cause dysplasia in the erythroid lineage and granulocytic lineage, respectively. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Congenital dyserythropoietic anemia'</a> and  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Lobulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sideroblastic</strong> <strong>anemias</strong> – Sideroblastic anemias comprise a spectrum of acquired and heritable erythropoietic disorders caused by abnormalities of heme synthesis and mitochondrial function  (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 4</a>). Detection of ring sideroblasts requires exclusion of other causes of acquired sideroblastic anemia (eg, copper deficiency, medications, excessive alcohol use). Females should be evaluated for X-linked sideroblastic anemia (XLSA) since they may present in adulthood with pathologic features indistinguishable from MDS with ring sideroblasts. Testing for XLSA is not necessary in individuals with one of the commonly acquired mutations in the <em>SF3B1</em> gene, which confirms an MDS or myeloproliferative neoplasm/MDS overlap (ie, associated with <em>JAK2</em> mutation) and excludes a congenital sideroblastic anemia. (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management"</a> and  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias"</a>.)</p><p></p><p class="headingAnchor" id="H3839085468"><span class="h2">Cytopenias</span><span class="headingEndMark"> — </span>Evaluation for cytopenias includes history, physical examination, screening laboratory studies, and may require bone marrow examination and other specialized studies, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutritional</strong> – Deficiency of vitamin B12, folate, or copper, or zinc excess should be excluded by clinical evaluation and laboratory testing. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Initial evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Numerous medications can cause individual cytopenias or pancytopenia. Evaluation of a suspected adverse effect of a medication is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Suspected medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic cytopenia of undetermined significance (ICUS) and clonal cytopenia of undetermined significance (CCUS)</strong> – ICUS<strong> </strong>refers to persistent cytopenias in the absence of significant dysplasia, evidence of other hematologic or nonhematologic cause for cytopenia, and any of the specific cytogenetic abnormalities that are considered presumptive evidence of MDS.</p><p></p><p class="bulletIndent1">CCUS describes a patient with a clonal mutation that does not meet criteria for MDS (ie, is not an MDS-defining cytogenetic abnormality) and an unexplained cytopenia, but no substantial dysplasia or other evidence of another hematologic neoplasm.</p><p></p><p class="bulletIndent1">ICUS and CCUS are described separately. (See  <a class="medical medical_review" href="/z/d/html/121985.html" rel="external">"Idiopathic and clonal cytopenias of uncertain significance (ICUS and CCUS)", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myelofibrosis</strong> – Mild to moderate bone marrow fibrosis is common with MDS, and a small percentage of patients display marked fibrosis that is similar to that in patients with primary myelofibrosis (PMF). Both conditions are associated with pancytopenia, but fibrotic MDS can be distinguished from PMF by the presence of significant dysplasia, diagnostic chromosomal abnormalities, lack of splenomegaly, and absence of mutations that are characteristic for PMF and other myeloproliferative neoplasms  (<a class="graphic graphic_table graphicRef110227" href="/z/d/graphic/110227.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef110226" href="/z/d/graphic/110226.html" rel="external">table 6</a>). Mutations of <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> are present in &gt;90 percent of patients with PMF, whereas only <em>JAK2</em> mutations are found in MDS, and these are seen in only 5 percent of cases [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aplastic anemia (AA)/paroxysmal nocturnal hemoglobinuria (PNH)</strong> – Most patients with MDS have a hypercellular bone marrow, but a minority have hypoplastic MDS that can resemble AA. MDS can generally be distinguished from AA by the characteristic dysplasia, ring sideroblasts, and/or karyotypic/molecular abnormalities. Although patients with MDS can have small populations of CD55/59-deficient PNH cells, few display typical PNH clinical manifestations (eg, robust hemolysis, thrombosis) [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3680908181"><span class="h2">Clonal disorders</span><span class="headingEndMark"> — </span>Certain non-malignant clonal disorders may be associated with cytopenias and/or dysplasia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonal hematopoiesis of indeterminate potential (CHIP)</strong> – CHIP refers to somatic mutations of genes associated with hematologic malignancies, in the absence of other diagnostic criteria for a hematologic malignancy [<a href="#rid74">74</a>]. Individuals with CHIP do not meet criteria for MDS, PNH, monoclonal gammopathy of undetermined significance, or monoclonal B cell lymphocytosis. (See  <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">"Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis", section on 'Clonal hematopoiesis of indeterminate potential (CHIP)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonal cytopenia of uncertain significance (CCUS)</strong> – CCUS describes patients with unexplained cytopenias and a clonal mutation that does not meet criteria for MDS or another hematologic neoplasm. (See  <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">"Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis", section on 'Clonal cytopenia of uncertain significance (CCUS)'</a>.)</p><p></p><p class="headingAnchor" id="H1839882269"><span class="h2">Acute myeloid leukemia (AML)</span><span class="headingEndMark"> — </span>AML and MDS lie along a disease continuum and the distinction between them is based on the blast percentage and/or the presence of certain cytogenetic/molecular features. Diagnosis and classification of AML are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.)</p><p>ICC and WHO5 classify cases of MDS with excess blasts differently (described above). (See <a class="local">'Classification'</a> above.)</p><p>Both ICC and WHO5 exclude the diagnosis of MDS from cases with any of the following genetic abnormalities, which are considered diagnostic for AML (without regard to the blast count):</p><p class="bulletIndent1"><span class="glyph">●</span>t(8;21)(q22;q22); <em>RUNX1-RUNX1T1</em> (previously <em>AML1-ETO</em>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>t(15;17)(q24.1;q21.1); <em>PML</em>-<em>RARA</em></p><p></p><p class="headingAnchor" id="H64021188"><span class="h2">MDS/MPN syndromes</span><span class="headingEndMark"> — </span>The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include disorders where both dysplastic and proliferative features coexist [<a href="#rid62">62,63</a>]. Cases with prominent dysplastic and myeloproliferative features should be classified as MDS/MPN, rather than MDS.</p><p>MDS/MPN syndromes include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic myelomonocytic leukemia (CMML)</strong> – The most common MDS/MPN is CMML, which is characterized by sustained peripheral blood monocytosis and somatic mutations that overlap with those seen in MDS.</p><p></p><p class="bulletIndent1">CMML manifests in the peripheral blood with monocytosis of ≥0.5 x 10<sup>9</sup>/L and ≥10 percent of white blood cells; cytopenias; &lt;20 percent blasts; and evidence of clonality. Both ICC and WHO5 distinguish between a myeloproliferative subtype and a myelodysplastic subtype of CMML and exclude the diagnosis of MDS in cases with persistent leukocytosis (WBC ≥13.0 x<sup> </sup>10<sup>9</sup>/L), thrombocytosis (platelets ≥450 x<sup> </sup>10<sup>9</sup>/L), and monocytosis, although their names and diagnostic criteria for CMML subtypes differ [<a href="#rid62">62,63</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS/MPN with ring sideroblasts/</strong><strong><em>SF3B1</em></strong><strong> mutation and thrombocytosis</strong> – This disorder includes platelets ≥450 x 10<sup>9</sup>/L and either ring sideroblasts or <em>SF3B1</em> mutation, but ICC and WHO5 differ in naming and classification of these cases [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Other MDS/MPN subtypes include atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML), and MDS/MPN, unclassifiable.</p><p></p><p>Further descriptions and diagnostic criteria are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'MDS/MPN syndromes'</a>.)</p><p class="headingAnchor" id="H628743876"><span class="h2">VEXAS syndrome</span><span class="headingEndMark"> — </span>This is a clonal disorder that occurs almost exclusively in males, which is associated with macrocytic anemia, thrombocytopenia, myeloid dyspoiesis, and inflammatory symptoms, such as alveolitis, ear and nose chondritis, and various skin conditions [<a href="#rid75">75</a>]. It is strongly associated with mutations in <em>UBA1</em>, an X-linked gene that encodes an E1 ubiquitin ligase required for initiation of ubiquitylation of proteins. Cytoplasmic vacuoles in erythroid and myeloid precursors may suggest VEXAS, but copper deficiency, excessive alcohol use, and other disorders may produce similar changes. Diagnosis requires identification of <em>UBA1</em> mutations by DNA sequencing. Very rarely, VEXAS syndrome has been reported in females [<a href="#rid76">76-79</a>]. </p><p class="headingAnchor" id="H2977252463"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116777.html" rel="external">"Society guideline links: Myelodysplastic syndromes"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/120173.html" rel="external">"Society guideline links: Bone marrow failure syndromes"</a>.)</p><p class="headingAnchor" id="H46"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16328.html" rel="external">"Patient education: Myelodysplastic syndromes (MDS) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/692.html" rel="external">"Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H47"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description </strong>–<strong> </strong>Myelodysplastic syndromes/neoplasms (MDS) are diverse hematologic malignancies characterized by cytopenias (ie, anemia, neutropenia, and/or thrombocytopenia), morphologic dysplasia, ineffective hematopoiesis, recurrent cytogenetic/genetic abnormalities, and increased risk for developing acute myeloid leukemia (AML) or bone marrow failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Median age is 70 years, and the incidence increases with age. Most MDS subtypes (except MDS with 5q deletion), have male predominance. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Fatigue, infections, bruising, or other symptoms associated with cytopenias are common, but some patients are asymptomatic and come to medical attention due to abnormalities on routine blood tests. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – Includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – Symptoms related to cytopenias (eg, fatigue, infections, bleeding/bruising), nutritional status, alcohol use, medications, toxins, prior cytotoxic treatments, comorbid illnesses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Complete blood count (CBC) and blood smear may reveal cytopenias and morphologic abnormalities  (<a class="graphic graphic_table graphicRef82345" href="/z/d/graphic/82345.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow</strong> – Microscopy and cytogenetic/molecular features are required for diagnosis and classification. (See <a class="local">'Bone marrow examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – MDS should be considered in any patient with unexplained cytopenia(s) or clinical symptoms associated with anemia, infections, or bleeding/bruising; morphologic dysplasia of blood or marrow; or unexplained bone marrow failure. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Diagnosis of MDS requires persistent cytopenia(s) and &lt;20 percent blasts in peripheral blood (PB)/bone marrow (BM) <strong>plus either</strong> characteristic cytogenetic/molecular features <strong>or</strong> dysplastic features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytopenia(s)</strong> – One or more cytopenias not explained by a drug, toxin, vitamin deficiency, infection, or other condition:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hemoglobin</strong> – &lt;10 g/dL (100 g/L)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Absolute neutrophil count (ANC)</strong> – &lt;1.8 x 10<sup>9</sup>/L (&lt;1800/microL)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Platelets</strong> – &lt;100 x 10<sup>9</sup>/L (&lt;100,000/microL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blasts</strong> – &lt;20 percent blasts</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytogenetic abnormalities</strong> – Specific cytogenetic/molecular findings are sufficient to diagnose MDS in a patient with unexplained cytopenias (even without dysplasia), while others exclude the diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – For patients without MDS-defining cytogenetic/molecular findings, diagnosis requires all of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytopenia</strong> – Cytopenia in ≥1 lineage</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – Morphologic dysplasia of ≥10 percent of nucleated cells in ≥1 lineage</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blast count </strong>– &lt;20 percent blasts in blood and marrow</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – MDS should be classified using either of the following systems; importantly, they apply different names and criteria to MDS subtypes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>International Consensus Classification (ICC) </strong>–<strong> </strong>Organized according to (see <a class="local">'International Consensus Classification (ICC)'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Specific genetic or karyotypic abnormalities</strong> – Includes MDS with mutated <em>SF3B1</em> and MDS with del(5q)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dysplasia</strong> – Various categories of MDS, not otherwise specified (NOS) according to 0, 1, or ≥2 affected lineages</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Excess blasts </strong>– Increased blasts; cases with BM/PB blasts 10-19 percent are labeled MDS/AML</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>World Health Organization 5</strong><strong><sup>th</sup></strong><strong> edition (WHO5)</strong> – Organized according to (see <a class="local">'World Health Organization 5th edition (WHO5)'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Defining genetic abnormalities </strong>– Includes MDS with low blasts and isolated del(5q), <em>SF3B1</em> mutation, and biallelic <em>TP53</em> inactivation</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Morphologically defined</strong> – Includes categories with low blasts, hypoplastic bone marrow, fibrosis, and increased blasts</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – MDS must be distinguished from other causes of cytopenias, dysplasia, and clonality, and from other hematologic malignancies (eg, AML, myelodysplastic/myeloproliferative neoplasms). (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Explorer. Breast: Recent trends in SEER age-adjusted incidence rates, 2000-2019. Available at: https://seer.cancer.gov/statistics-network/explorer/application.html?site=55&amp;data_type=1&amp;graph_type=2&amp;compareBy=age_range&amp;chk_age_range_16=16&amp;chk_age_range_15=15&amp;rate_type=2&amp;sex=3&amp;race=1&amp;stage=101&amp;advopt_precision=1&amp;advopt_show_ci=on&amp;advopt_display=2.</li><li><a class="nounderline abstract_t">Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. Blood 2018; 131:1406.</a></li><li><a class="nounderline abstract_t">Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010; 28:2847.</a></li><li><a class="nounderline abstract_t">Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003; 121:270.</a></li><li><a class="nounderline abstract_t">Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104:788.</a></li><li><a class="nounderline abstract_t">Abel GA, Efficace F, Buckstein RJ, et al. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica 2016; 101:781.</a></li><li><a class="nounderline abstract_t">Efficace F, Gaidano G, Breccia M, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol 2015; 168:361.</a></li><li><a class="nounderline abstract_t">Sekeres MA, Taylor J. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA 2022; 328:872.</a></li><li><a class="nounderline abstract_t">Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica 2012; 97:1459.</a></li><li><a class="nounderline abstract_t">Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010; 116:2174.</a></li><li><a class="nounderline abstract_t">Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol 2012; 30:1087.</a></li><li><a class="nounderline abstract_t">Grignano E, Jachiet V, Fenaux P, et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol 2018; 97:2015.</a></li><li><a class="nounderline abstract_t">Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100:822.</a></li><li><a class="nounderline abstract_t">Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018; 14:576.</a></li><li><a class="nounderline abstract_t">Weeks LD, Marinac CR, Redd R, et al. Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2022; 139:1246.</a></li><li><a class="nounderline abstract_t">Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004; 103:2019.</a></li><li><a class="nounderline abstract_t">Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005; 105:443.</a></li><li><a class="nounderline abstract_t">Steensma DP, Porcher JC, Hanson CA, et al. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. Br J Haematol 2007; 139:439.</a></li><li><a class="nounderline abstract_t">Steensma DP, Viprakasit V, Hendrick A, et al. Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome. Blood 2004; 103:1518.</a></li><li><a class="nounderline abstract_t">Higgs DR. Gene regulation in hematopoiesis: new lessons from thalassemia. Hematology Am Soc Hematol Educ Program 2004; :1.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer 1989; 64:2506.</a></li><li><a class="nounderline abstract_t">Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007; 139:265.</a></li><li><a class="nounderline abstract_t">Kodali D, Mesa H, Rawal A, et al. Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes. Leuk Lymphoma 2007; 48:2375.</a></li><li><a class="nounderline abstract_t">Kuriyama K, Tomonaga M, Matsuo T, et al. Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol 1986; 63:665.</a></li><li><a class="nounderline abstract_t">Hast R, Nilsson I, Widell S, Ost A. Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes. Leuk Res 1989; 13:173.</a></li><li><a class="nounderline abstract_t">Davey FR, Erber WN, Gatter KC, Mason DY. Abnormal neutrophils in acute myeloid leukemia and myelodysplastic syndrome. Hum Pathol 1988; 19:454.</a></li><li><a class="nounderline abstract_t">Langenhuijsen MM. Neutrophils with ring-shaped nuclei in myeloproliferative disease. Br J Haematol 1984; 58:227.</a></li><li><a class="nounderline abstract_t">Gallardo R, Kranwinkel RN. Pseudo-Chédiak-Higashi anomaly. Am J Clin Pathol 1985; 83:127.</a></li><li><a class="nounderline abstract_t">Rassam SM, Roderick P, al-Hakim I, Hoffbrand AV. A myelokathexis-like variant of myelodysplasia. Eur J Haematol 1989; 42:99.</a></li><li><a class="nounderline abstract_t">Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 2015; 29:66.</a></li><li><a class="nounderline abstract_t">Parmentier S, Schetelig J, Lorenz K, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica 2012; 97:723.</a></li><li><a class="nounderline abstract_t">Senent L, Arenillas L, Luño E, et al. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 2013; 98:568.</a></li><li><a class="nounderline abstract_t">Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008; 93:1712.</a></li><li><a class="nounderline abstract_t">Goasguen JE, Bennett JM, Bain BJ, et al. Morphological evaluation of monocytes and their precursors. Haematologica 2009; 94:994.</a></li><li><a class="nounderline abstract_t">Doll DC, List AF. Myelodysplastic syndromes. West J Med 1989; 151:161.</a></li><li><a class="nounderline abstract_t">Beris P. Primary clonal myelodysplastic syndromes. Semin Hematol 1989; 26:216.</a></li><li><a class="nounderline abstract_t">Matsushima T, Murakami H, Sawamura M, et al. Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group. Br J Haematol 1993; 84:636.</a></li><li><a class="nounderline abstract_t">Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984; 58:217.</a></li><li><a class="nounderline abstract_t">Yunis JJ, Rydell RE, Oken MM, et al. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood 1986; 67:1721.</a></li><li><a class="nounderline abstract_t">Verburgh E, Achten R, Maes B, et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol 2003; 21:273.</a></li><li><a class="nounderline abstract_t">Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ. Red cell aplasia in myelodysplastic syndrome. J Clin Pathol 1991; 44:431.</a></li><li><a class="nounderline abstract_t">Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003; 101:3386.</a></li><li><a class="nounderline abstract_t">Head DR, Kopecky K, Bennett JM, et al. Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative Study. Cancer 1989; 64:2199.</a></li><li><a class="nounderline abstract_t">Mathew P, Tefferi A, Dewald GW, et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood 1993; 81:1040.</a></li><li><a class="nounderline abstract_t">Wong KF, Chan JK. Are 'dysplastic' and hypogranular megakaryocytes specific markers for myelodysplastic syndrome? Br J Haematol 1991; 77:509.</a></li><li><a class="nounderline abstract_t">Craig JW, Hasserjian RP, Kim AS, et al. Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Mod Pathol 2020; 33:1135.</a></li><li><a class="nounderline abstract_t">Sultan C, Sigaux F, Imbert M, Reyes F. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol 1981; 49:11.</a></li><li><a class="nounderline abstract_t">Pagliuca A, Layton DM, Manoharan A, et al. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol 1989; 71:499.</a></li><li><a class="nounderline abstract_t">Lambertenghi-Deliliers G, Orazi A, Luksch R, et al. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991; 78:161.</a></li><li><a class="nounderline abstract_t">Ohyashiki K, Sasao I, Ohyashiki JH, et al. Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. Cancer 1991; 68:178.</a></li><li><a class="nounderline abstract_t">Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65:1364.</a></li><li><a class="nounderline abstract_t">Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979; 43:185.</a></li><li><a class="nounderline abstract_t">van de Loosdrecht AA, Alhan C, Béné MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94:1124.</a></li><li><a class="nounderline abstract_t">Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102:394.</a></li><li><a class="nounderline abstract_t">Scott BL, Wells DA, Loken MR, et al. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008; 112:2681.</a></li><li><a class="nounderline abstract_t">Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005; 124:170.</a></li><li><a class="nounderline abstract_t">Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010; 116:4549.</a></li><li><a class="nounderline abstract_t">Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26:1730.</a></li><li><a class="nounderline abstract_t">van de Loosdrecht AA, Ireland R, Kern W, et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 2013; 54:472.</a></li><li><a class="nounderline abstract_t">Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014; 28:1793.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">Matsuda A, Germing U, Jinnai I, et al. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia 2007; 21:678.</a></li><li><a class="nounderline abstract_t">Banerjee R, Halil O, Bain BJ, et al. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation 2000; 70:1608.</a></li><li><a class="nounderline abstract_t">Kennedy GA, Kay TD, Johnson DW, et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology 2002; 34:263.</a></li><li><a class="nounderline abstract_t">Singh NK, Nagendra S. Reversible neutrophil abnormalities related to supratherapeutic valproic acid levels. Mayo Clin Proc 2008; 83:600.</a></li><li><a class="nounderline abstract_t">Taegtmeyer AB, Halil O, Bell AD, et al. Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir. Transplantation 2005; 80:127.</a></li><li><a class="nounderline abstract_t">Gibbs SD, Westerman DA, McCormack C, et al. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005; 130:87.</a></li><li><a class="nounderline abstract_t">Schmitz LL, McClure JS, Litz CE, et al. Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am J Clin Pathol 1994; 101:67.</a></li><li><a class="nounderline abstract_t">Takahashi K, Yabe M, Shapira I, et al. Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. Leuk Res 2012; 36:1376.</a></li><li><a class="nounderline abstract_t">Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106:1207.</a></li><li><a class="nounderline abstract_t">Pu JJ, Hu R, Mukhina GL, et al. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica 2012; 97:1225.</a></li><li><a class="nounderline abstract_t">Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126:9.</a></li><li><a class="nounderline abstract_t">Beck DB, Ferrada MA, Sikora KA, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2020; 383:2628.</a></li><li><a class="nounderline abstract_t">Beck DB, Grayson PC, Kastner DL. Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. Reply. N Engl J Med 2021; 384:2164.</a></li><li><a class="nounderline abstract_t">Luzzatto L, Risitano AM, Notaro R. Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2021; 384:2164.</a></li><li><a class="nounderline abstract_t">Diarra A, Duployez N, Terriou L. Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2021; 384:2163.</a></li><li><a class="nounderline abstract_t">Arlet JB, Terrier B, Kosmider O. Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2021; 384:2163.</a></li></ol></div><div id="topicVersionRevision">Topic 4492 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://seer.cancer.gov/statistics-network/explorer/application.html?site=55&amp;data_type=1&amp;graph_type=2&amp;compareBy=age_range&amp;chk_age_range_16=16&amp;chk_age_range_15=15&amp;rate_type=2&amp;sex=3&amp;race=1&amp;stage=101&amp;advopt_precision=1&amp;advopt_show_ci=on&amp;advopt_display=2" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Explorer. Breast: Recent trends in SEER age-adjusted incidence rates, 2000-2019. Available at: https://seer.cancer.gov/statistics-network/explorer/application.html?site=55&amp;data_type=1&amp;graph_type=2&amp;compareBy=age_range&amp;chk_age_range_16=16&amp;chk_age_range_15=15&amp;rate_type=2&amp;sex=3&amp;race=1&amp;stage=101&amp;advopt_precision=1&amp;advopt_show_ci=on&amp;advopt_display=2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438960" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : How I treat myelodysplastic syndromes of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421543" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694248" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15973668" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26944474" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25272332" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36066514" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733024" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Infections in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20162709" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cause of death in patients with lower-risk myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22331938" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30091023" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Autoimmune manifestations associated with myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19259097" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risks of myeloid malignancies in patients with autoimmune conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30046148" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inflammaging: a new immune-metabolic viewpoint for age-related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34875037" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14592816" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358626" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17910635" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576055" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561673" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gene regulation in hematopoiesis: new lessons from thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561673" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gene regulation in hematopoiesis: new lessons from thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2819658" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764468" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18067013" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3460627" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2927174" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2835302" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Abnormal neutrophils in acute myeloid leukemia and myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6591944" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neutrophils with ring-shaped nuclei in myeloproliferative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966432" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pseudo-Chédiak-Higashi anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2914601" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A myelokathexis-like variant of myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24935723" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180437" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23065505" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838480" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19535346" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Morphological evaluation of monocytes and their precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2672599" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2675318" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Primary clonal myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8217821" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6477833" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3708158" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525519" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1904455" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Red cell aplasia in myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506028" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2804910" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8427985" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The 5q- syndrome: a single-institution study of 43 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025576" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Are 'dysplastic' and hypogranular megakaryocytes specific markers for myelodysplastic syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31896808" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7272222" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute myelodysplasia with myelofibrosis: a report of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2640542" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1712222" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2049740" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3857944" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/508627" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The reticulin content of bone marrow in acute leukaemia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546437" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649150" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606877" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040286" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20572043" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22307178" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22916713" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24919805" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17268513" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152223" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Neutrophil dysplasia caused by mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12109788" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452694" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Reversible neutrophil abnormalities related to supratherapeutic valproic acid levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003243" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982349" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7506481" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Morphologic and quantitative changes in blood and marrow cells following growth factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22917767" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860661" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315493" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931582" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33108101" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077654" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. Reply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077653" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077652" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077651" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
